MARKET

ALT

ALT

Altimmune
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.800
-0.030
-1.64%
Opening 11:06 01/29 EST
OPEN
1.820
PREV CLOSE
1.830
HIGH
1.820
LOW
1.760
VOLUME
84.73K
TURNOVER
--
52 WEEK HIGH
5.94
52 WEEK LOW
1.510
MARKET CAP
40.09M
P/E (TTM)
-0.4158
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ALT and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ALT News

  • Altimmune up 6% premarket on encouraging ALT-702 data
  • seekingalpha.5d ago
  • Altimmune Reports Results For ALT-702 In Preclinical Model Of Colorectal Cancer: Shows 'systemic activity of ALT-702 following local administration,' Go Granted US Patent
  • Benzinga.6d ago
  • Altimmune Announces Positive Results for ALT-702 in Preclinical Model of Colorectal Cancer
  • GlobeNewswire.6d ago
  • Altimmune to Present at the 2020 NASH-TAG Conference
  • GlobeNewswire.01/07 13:43

More

Industry

Biotechnology & Medical Research
+0.10%
Pharmaceuticals & Medical Research
+0.42%

Hot Stocks

Name
Price
%Change

About ALT

Altimmune Inc is a clinical-stage immunotherapeutics company. The Company is focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The Company’s product candidates include ALT-801, HepTcell, ALT-702, NasoVAX and NasoShield. HepTcell is a synthetic peptide immunotherapeutic candidate designed to break immune tolerance in chronic Hepatitis B infection. ALT-702, a TLR7/8 agonist conjugate, is a tumor immunostimulant product candidate that has the potential to safely elicit or improve immune responses in a variety of cancer indications. NasoVAX, its influenza vaccine candidate that stimulate multiple arms of the immune system and offers the potential to stop the infection and the spread of flu, while being easier to administer through an intranasal spray. NasoShield is an intranasal anthrax vaccine candidate that is designed to provide more rapid and stable protection than the only approved anthrax vaccine.
More

Webull offers Altimmune Inc (ALT) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.